Thyroid Eye Disease (TED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Thyroid Eye Disease (TED) Market Outlook

Thelansis’s “Thyroid Eye Disease (TED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thyroid Eye Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thyroid Eye Disease (TED) Overview

Thyroid eye disease (TED) is an autoimmune disorder characterized by inflammation of orbital tissues. It exhibits diverse clinical manifestations, including lymphocytic cell infiltration, expansion of orbital fat, and swelling of extraocular muscles. The severity of TED stems from its potential to cause vision impairment, functional limitations, and cosmetic alterations. Concurrently, ocular and systemic manifestations manifest in 40% of TED cases. At the onset, hyperthyroidism is predominant in 85–90% of TED cases, with a smaller proportion presenting as euthyroid or hypothyroid. Common initial symptoms include dry eyes, redness, diplopia, and eye pain, often accompanied by eyelid retraction, exophthalmos, and restricted eye movements. Various grading systems, such as the European Group on Graves Orbitopathy (EUGOGO) protocol, VISION classification (assessing vision, inflammation, strabismus, and appearance), NOSPECS classification, and Mourits system, aid in determining TED severity and tracking disease activity. Due to the diverse presentations, tailored clinical evaluation and ancillary testing are necessary. TED can mimic other conditions, including orbital tumors, myasthenia gravis, and systemic inflammatory diseases, making accurate diagnosis challenging. Teprotumumab (Tepezza), an FDA-approved immunotherapy, targets the insulin-like growth factor-1 receptor (IGF-1R) on orbital fibroblasts, inhibiting their activation and signaling.

• In the United States, TED incidence is higher in women, with an annual rate of 16 per 100,000 person-years compared to 3 per 100,000 person-years in men. The highest prevalence occurs in individuals aged 50–54 years, with women consistently exhibiting a threefold higher prevalence rate across different age groups and racial/ethnic backgrounds.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2024-2034

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: